Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia

Muscle and Nerve

Volumn 48, Issue 5, 2013, Pages 838-839

  Pars, Kaweh ^a   Garde, Niklas ^a   Skripuletz, Thomas ^a   Pul, Refik ^a   Dengler, Reinhard ^a   Stangel, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; METHOTREXATE; PREDNISOLONE;

AGED; BULBAR PARALYSIS; CASE REPORT; DISEASE COURSE; DRUG DOSE REDUCTION; DYSPHAGIA; GRIP STRENGTH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; LETTER; MALE; MUSCLE BIOPSY; PARAPLEGIA; PARESIS; POLYMYOSITIS; PRIORITY JOURNAL; QUADRIPLEGIA;

AGED; DEGLUTITION DISORDERS; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, INTRADERMAL; MALE; MYOSITIS, INCLUSION BODY; TREATMENT OUTCOME;

EID: 84886747065     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23895     Document Type: Letter

References (13)

1. Hokkoku K, Sonoo M, Higashihara M, Stalberg E, Shimizu T. Electromyographs of the flexor digitorum profundus muscle are useful for the diagnosis of inclusion body myositis. Muscle Nerve 2012;46:181-186.
2. Chai Y, Bertorini TE, McGrew FA. Hereditary inclusion-body myopathy associated with cardiomyopathy: report of two siblings. Muscle Nerve 2011;43:133-136.
3. Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep 2013;13:321.
4. Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28.
5. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327.
6. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-716.
7. Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003;24:256-259.
8. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78:1009-1015.
9. Stangel M, Gold R. Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010 [in German]. Nervenarzt 2011;82:415-430.
10. Stangel M, Gold R. Use of i.v. immunoglobulins in neurology. Evidence-based consensus [in German]. Nervenarzt 2004;75:801-815.
11. Bayas A, Gold R, Naumann M. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions. J Neurol Sci 2013;324:53-56.
12. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 2010;75:1377-1380.
13. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326.